These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 22218072)

  • 1. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.
    Bifone A; Gozzi A
    Expert Opin Drug Discov; 2012 Nov; 7(11):1071-82. PubMed ID: 22971143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult neurogenesis pharmacology in neurological diseases and disorders.
    Taupin P
    Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.
    Safavi M; Sabourian R; Abdollahi M
    Expert Opin Drug Discov; 2016 Oct; 11(10):939-56. PubMed ID: 27454411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foreword: neurodegenerative diseases: challenges and opportunities.
    Cuny GD
    Future Med Chem; 2012 Sep; 4(13):1647-9. PubMed ID: 22924500
    [No Abstract]   [Full Text] [Related]  

  • 13. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of imaging in proof of concept for CNS drug discovery and development.
    Wong DF; Tauscher J; Gründer G
    Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
    Rossi T; Braggio S
    Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research.
    Leiser SC; Dunlop J; Bowlby MR; Devilbiss DM
    Biochem Pharmacol; 2011 Jun; 81(12):1408-21. PubMed ID: 20937262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.